These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 12540231)

  • 1. Phenethyl amides as novel noncovalent inhibitors of hepatitis C virus NS3/4A protease: discovery, initial SAR, and molecular modeling.
    Colarusso S; Koch U; Gerlach B; Steinkühler C; De Francesco R; Altamura S; Matassa VG; Narjes F
    J Med Chem; 2003 Jan; 46(3):345-8. PubMed ID: 12540231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toward second generation hepatitis C virus NS3 serine protease inhibitors: discovery of novel P4 modified analogues with improved potency and pharmacokinetic profile.
    Arasappan A; Padilla AI; Jao E; Bennett F; Bogen SL; Chen KX; Pike RE; Sannigrahi M; Soares J; Venkatraman S; Vibulbhan B; Saksena AK; Girijavallabhan V; Tong X; Cheng KC; Njoroge FG
    J Med Chem; 2009 May; 52(9):2806-17. PubMed ID: 19371095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capped dipeptide phenethylamide inhibitors of the HCV NS3 protease.
    Nizi E; Koch U; Ontoria JM; Marchetti A; Narjes F; Malancona S; Matassa VG; Gardelli C
    Bioorg Med Chem Lett; 2004 May; 14(9):2151-4. PubMed ID: 15080998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design.
    Venkatraman S; Njoroge FG; Girijavallabhan VM; Madison VS; Yao NH; Prongay AJ; Butkiewicz N; Pichardo J
    J Med Chem; 2005 Aug; 48(16):5088-91. PubMed ID: 16078825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
    Njoroge FG; Chen KX; Shih NY; Piwinski JJ
    Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of hepatitis C virus NS3/4A: alpha-ketoamide based macrocyclic inhibitors.
    Avolio S; Robertson K; Hernando JI; DiMuzio J; Summa V
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2295-8. PubMed ID: 19285390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and structure-activity relationship of P1-P3 ketoamide derived macrocyclic inhibitors of hepatitis C virus NS3 protease.
    Venkatraman S; Velazquez F; Wu W; Blackman M; Chen KX; Bogen S; Nair L; Tong X; Chase R; Hart A; Agrawal S; Pichardo J; Prongay A; Cheng KC; Girijavallabhan V; Piwinski J; Shih NY; Njoroge FG
    J Med Chem; 2009 Jan; 52(2):336-46. PubMed ID: 19102654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-peptidic small-molecule inhibitors of the single-chain hepatitis C virus NS3 protease/NS4A cofactor complex discovered by structure-based NMR screening.
    Wyss DF; Arasappan A; Senior MM; Wang YS; Beyer BM; Njoroge FG; McCoy MA
    J Med Chem; 2004 May; 47(10):2486-98. PubMed ID: 15115392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of glycine alpha-ketoamide HCV NS3 protease inhibitors: effect of carboxylic acid isosteres.
    Han W; Jiang X; Hu Z; Wasserman ZR; Decicco CP
    Bioorg Med Chem Lett; 2005 Aug; 15(15):3487-90. PubMed ID: 15982872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P4 capped amides and lactams as HCV NS3 protease inhibitors with improved potency and DMPK profile.
    Nair LG; Sannigrahi M; Bogen S; Pinto P; Chen KX; Prongay A; Tong X; Cheng KC; Girijavallabhan V; George Njoroge F
    Bioorg Med Chem Lett; 2010 Jan; 20(2):567-70. PubMed ID: 20004570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus NS3-4A serine protease inhibitors: SAR of P'2 moiety with improved potency.
    Arasappan A; Njoroge FG; Chan TY; Bennett F; Bogen SL; Chen K; Gu H; Hong L; Jao E; Liu YT; Lovey RG; Parekh T; Pike RE; Pinto P; Santhanam B; Venkatraman S; Vaccaro H; Wang H; Yang X; Zhu Z; Mckittrick B; Saksena AK; Girijavallabhan V; Pichardo J; Butkiewicz N; Ingram R; Malcolm B; Prongay A; Yao N; Marten B; Madison V; Kemp S; Levy O; Lim-Wilby M; Tamura S; Ganguly AK
    Bioorg Med Chem Lett; 2005 Oct; 15(19):4180-4. PubMed ID: 16087332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological activity of macrocyclic inhibitors of hepatitis C virus (HCV) NS3 protease.
    Chen KX; Njoroge FG; Prongay A; Pichardo J; Madison V; Girijavallabhan V
    Bioorg Med Chem Lett; 2005 Oct; 15(20):4475-8. PubMed ID: 16112859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.
    Llinàs-Brunet M; Bailey MD; Bolger G; Brochu C; Faucher AM; Ferland JM; Garneau M; Ghiro E; Gorys V; Grand-Maître C; Halmos T; Lapeyre-Paquette N; Liard F; Poirier M; Rhéaume M; Tsantrizos YS; Lamarre D
    J Med Chem; 2004 Mar; 47(7):1605-8. PubMed ID: 15027850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus NS3-4A serine protease inhibitors: SAR of new P1 derivatives of SCH 503034.
    Bogen S; Arasappan A; Pan W; Ruan S; Padilla A; Saksena AK; Girijavallabhan V; Njoroge FG
    Bioorg Med Chem Lett; 2008 Jul; 18(14):4219-23. PubMed ID: 18547808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P4 cap modified tetrapeptidyl alpha-ketoamides as potent HCV NS3 protease inhibitors.
    Sun DX; Liu L; Heinz B; Kolykhalov A; Lamar J; Johnson RB; Wang QM; Yip Y; Chen SH
    Bioorg Med Chem Lett; 2004 Aug; 14(16):4333-8. PubMed ID: 15261297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease.
    Liverton NJ; Holloway MK; McCauley JA; Rudd MT; Butcher JW; Carroll SS; DiMuzio J; Fandozzi C; Gilbert KF; Mao SS; McIntyre CJ; Nguyen KT; Romano JJ; Stahlhut M; Wan BL; Olsen DB; Vacca JP
    J Am Chem Soc; 2008 Apr; 130(14):4607-9. PubMed ID: 18338894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide inhibitors of dengue virus NS3 protease. Part 2: SAR study of tetrapeptide aldehyde inhibitors.
    Yin Z; Patel SJ; Wang WL; Chan WL; Ranga Rao KR; Wang G; Ngew X; Patel V; Beer D; Knox JE; Ma NL; Ehrhardt C; Lim SP; Vasudevan SG; Keller TH
    Bioorg Med Chem Lett; 2006 Jan; 16(1):40-3. PubMed ID: 16246563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent 7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid-based macrocyclic inhibitors of hepatitis C virus NS3 protease.
    Chen KX; Njoroge FG; Pichardo J; Prongay A; Butkiewicz N; Yao N; Madison V; Girijavallabhan V
    J Med Chem; 2006 Jan; 49(2):567-74. PubMed ID: 16420042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
    Dahl G; Sandström A; Akerblom E; Danielson UH
    Antivir Ther; 2007; 12(5):733-40. PubMed ID: 17713156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization.
    Perni RB; Pitlik J; Britt SD; Court JJ; Courtney LF; Deininger DD; Farmer LJ; Gates CA; Harbeson SL; Levin RB; Lin C; Lin K; Moon YC; Luong YP; O'Malley ET; Rao BG; Thomson JA; Tung RD; Van Drie JH; Wei Y
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1441-6. PubMed ID: 15006379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.